Prostate cancer: the contribution of nuclear medicine
2000; Wiley; Volume: 86; Issue: s1 Linguagem: Inglês
10.1046/j.1464-410x.2000.00595.x
ISSN1464-410X
AutoresK. E. Britton, Mark Feneley, H. Jan, Vaseem Chengazi, M. Granowska,
Tópico(s)Prostate Cancer Diagnosis and Treatment
ResumoBJU InternationalVolume 86, Issue s1 p. 135-142 Prostate cancer: the contribution of nuclear medicine K.E. Britton, K.E. Britton Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorM.R. Feneley, M.R. Feneley Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorH. Jan, H. Jan Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorV.U. Chengazi, V.U. Chengazi Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorM. Granowska, M. Granowska Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this author K.E. Britton, K.E. Britton Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorM.R. Feneley, M.R. Feneley Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorH. Jan, H. Jan Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorV.U. Chengazi, V.U. Chengazi Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this authorM. Granowska, M. Granowska Departments of Nuclear Medicine and Urology, St Bartholomew's Hospital London, UKSearch for more papers by this author First published: 02 January 2002 https://doi.org/10.1046/j.1464-410X.2000.00595.xCitations: 5 Professor K.E. Britton, Department of Nuclear Medicine, St Bartholomew's Hospital, London EC1A 7BE, UK. e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Verrilli RA, Brady LW, Croll MN et al. Zinc-65 uptake by the prostate. J Urol 1962; 88: 664 6 2 Chisholm GD, Short MD, Ghanadian R, McRae CU, Glass HI. Radiozinc uptake and scintiscanning in prostatic disease. J Nucl Med 1974; 15: 749 52 3 Ghanadian R, Water SL, Chisholm GD. Investigations into the use of 77Br labelled 5-alpha-dihydrotestosterone for scanning the prostate. Eur J Nucl Med 1997; 2: 155 7 4 Tarle M, Padovan R, Spaventi S. The uptake of radioiodinated 5-alpha-dihydro-testosterone by the prostate of intact and castrated rats. Eur J Nucl Med 1981; 6: 79 83 5 Liu AJ, Katzenellenbogen JA, Van Brocklin HF et al. 20-[18F]-fluoromibolerone, a positron-emitting radiotracer for androgen receptors: synthesis and tissue distribution studies. J Nucl Med 1991; 32: 81 8 6 Liu A, Dence CS, Welch MJ et al. Fluorine-18-labelled androgens: radiochemical synthesis and tissue distribution studies on six fluorine substituted androgens, potential imaging agents for prostatic cancer. J Nucl Med 1992; 33: 724 34 7 Bergen B, Coffrey DS, Scott WW. Concepts and limitations of radiolabelled antiandrogens, oestrogens, or androgens as isotope scanning agents for the prostate. Invest Urol 1975; 13: 10 6 8 Eakins MN. The distribution of 75 Se-adenosyl selenomethionine in the rat with observations on its potential as a prostate scanning agent. Eur J Nucl Med 1979; 4: 101 3 9 Elsinga PH, Daemen BJ, Ishiwata K et al. Ornithine decarboxylase activity in prostate tumour: a feasibility study for PET with L-[5–14C]+ and L-[5–14C]-ornithine. Int J Radiation Applic Instrum – Part B; Nuclear Med Biol 1990; 17: 597 600 10 Hwang DR, Jerabek PA, Kadmon D et al. [18F] fluoroputrescine: preparation, biodistribution and mechanism of defluorination. Int J Radiation Applic Instrum – Part A Appl Radiation Isotopes 1986; 37: 607 12 11 Effert PJ, Bares R, Handt S et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-fluorine labelled deoxyglucose. J Urol 1996; 155: 994 8 12 Hoh CK, Seltzer MA, Franklin J et al. Positron emission tomography in urological oncology. J Urol 1998; 159: 347 56 13 Ricchiuti VS, Haas C, Resnick MI, Miraldi F. The accuracy of PET scanning is detecting prostatic fossa recurrence after radical prostatectomy. J Urol 1999; 161: 393 14 Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2 [F-18] fluoro- d-glucose . Radiology 1996; 199: 751 6 15 Yeh SDJ, Imbriaco M, Garza D et al. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by PETFDG whole body scanning. J Nucl Med 1995; 36: 198P 16 Gardiner RA, Fitzpatrick JM, Constable AR et al. Human Prostatic lymphoscintigraphy: a preliminary report. Br J Urol 1979; 51: 300 3 17 Gardiner RA, Fitzpatrick JM, Constable AR et al. Improved techniques in radionuclides imaging of prostatic lymph nodes. Br J Urol 1979; 51: 561 4 18 Stone AR, Merrick MV, Chisholm GD. Prostatic lymphoscintigraphy. Br J Urol 1979; 51: 556 60 19 Whitmore WF, Blute RD Jr, Kaplan WD et al. Radiocolloid scintigraphic mapping of the lymphatic drainage of the prostate. J Urol 1980; 124: 62 7 20 Babaian RJ & Lamki LM. Radioimmunoscintigraphy of prostate cancer. Semin Nucl Med 1989; 19: 309 21 21 Burgers KL, Hinkle GH, Haseman MK. Monoclonal antibody imaging of recurrent and metastatic prostate cancer. Semin Urol 1995; 13: 103 12 22 Vihko P, Heikkila J, Konturri M et al. Radioimaging of the prostate and metastases of prostatic carcinoma with 99m-Tc labelled prostatic acid phosphatase-specific antibodies and their Fab fragments. Ann Clin Res 1984; 16: 51 2 23 Meyers FJ, DeNardo SJ, Macey D et al. Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Prostate 1989; 14: 209 20 24 Neal CE, Swenson LC, Fanning J et al. Monoclonal antibodies in ovarian and prostate cancer. Sem Nucl Med 1993; 23: 114 26 25 Wynant GE, Murphy GP, Horoszewicz JS et al. Immuno-scintigraphy of prostate cancer: Preliminary results with 111-In-labelled monoclonal antibody 7E11C5.3. CYT-356). Prostate 1991; 18: 229 41 26 Troyer JK, Feng Q, Beckett ML et al. Molecular characterisation of the 7E11C5 prostate tumour associated antigen. J Urol 1993; 149: 333A 27 Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987; 7: 927 35 28 Wright GL, Haley C, Beckett ML et al. Expression of the prostate biomarker 7E11C5 in primary and metastatic prostate carcinoma. Proc Am Assoc Cancer Res 1994; 35: 223 29 Murphy GP. Lucy Wortham James Basic Research Award: Markers of prostatic carcinoma. Arch Surg 1991; 126: 1404 7 30 Barren RJ, Holmes EH, Boynton AL, Misrock SL, Murphy GP. Monoclonal antibody 7E11.C5 staining of viable LNCaP cells. Prostate 1997; 30: 65 8 31 Gulfo JV. Clinical utility of monoclonal antibodies in prostate cancer. In: NA Dawson, NJ Vogelzang, eds, Prostate Cancer. New York: Wiley-Liss, 1994: 77 94 32 Lopes AD, Davis WL, Rosenstraus MJ et al. Immunohistochemical and pharmacokinetic characterisation of the site specific immunoconjugate CYT 356 derived from antiprostate monoclonal antibody 7E11C5. Cancer Res 1990; 50: 6423 9 33 Mardirossian G, Brill AB, Dwyer KM, Kahn D, Nelp W. Radiation absorbed dose from Indium-111-CYT 356. J Nucl Med 1996; 37: 1583 8 34 Buraggi GL, Turrin A, Cascinelli N et al. Immuno-scintigraphy with antimelanoma monoclonal antibodies. In: P Cox, ed. Monographs in Nuclear Medicine. Vol 1. Immunoscintigraphy. Saariselka, Finland: Gordon and Breach Publishers, 1984: 215 53 35 Britton KE, Granowska M, Mather SJ. Radiolabelled antibodies in oncology. I. Technical aspects. Nuclear Med Comm 1991; 12: 65 76 36 Maguire RT, Pascucci VL, Maroli AN et al. Immuno-scintigraphy in patients with colorectal, ovarian and prostate cancer: Results with site-specific immunoconjugates. Cancer 1993; 72: 3453 62 37 Texter JH Jr & Neal C. Current applications of immunoscintigraphy in prostate cancer. J Nucl Med 1993; 34: 549 53 38 Scardino PT. Problems of prostate cancer. J Urol 1994; 152: 1677 8 39 Babaian RJ, Sayer J, Podoloff DA, Steelhammer LC, Bhadkamkar VA, Gulfo JV. Radioimmunoscintigraphy of pelvic lymph nodes with 111-indium labelled monoclonal antibody CYT 356. J Urol 1994; 152: 1952 5 40 Neal CE & Meis LC. Correlative imaging with monoclonal antibodies in colorectal, ovarian and prostate cancer. Semin Nucl Med 1994; 24: 272 85 41 Kahn D, Williams RD, Seldin DW et al. Radioimmuno-scintigraphy with 111-Indium labelled CYT-356 for the detection of occult prostate cancer recurrence. J Urol 1994; 152: 1490 5 42 Kotz D. Monoclonal antibody scan holds promise for prostate cancer imaging. J Nucl Med 1996; 4: 11N 15N 43 Haseman MK & Reed NL. Monoclonal antibody imaging for staging recurrent prostate cancer. J Nucl Med 1996; 37: 10P 44 Haseman MK, Reed NL, Rosenthal SA. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin Nucl Med 1996; 21: 704 13 45 Krynycki BR, Li Y, Ganeles A et al. Patterns of metastatic prostate cancer as determined by In-111 CYT-356 (Prostacint™) immunoscintigraphy. J Nucl Med 1996; 37: 10P 46 Sodee DB, Conant R, Chalfant M et al. Preliminary imaging results using Indium 111-labelled Cyt-356 (Prostascint™) in the detection of recurrent prostate cancer. Clin Nucl Med 1996; 21: 759 67 47 Murphy GP, Maguire RT, Rogers B et al. Comparison of serum PSMA, PSA levels with results of Cytogen-356 Prostascint scanning in prostatic cancer patients. Prostate 1997; 33: 281 5 48 Kahn D, Haseman MK, Libertino J et al. Indium-111 capromab pendetide (ProstaScint) imaging of patients with rising PSA post-prostatectomy. J Urol 1997; 158: 157 204 49 Hinkle GH, Burgers JK, Olsen JO et al. Prostate cancer abdominal metastases detected with Indium-111 capromab pendetide. J Nucl Med 1998; 39: 650 2 50 Levesque PE, Nieh PT, Zinman LN, Seldin DW, Libertino JA. Radiolabelled monoclonal antibody Indium 111-labelled CYT-356 localises extraprostatic recurrent carcinoma after prostatectomy. Urology 1998; 51: 978 84 51 Haseman MK. Capromab pendetide imaging of occult lymph node metastases. J Nucl Med 1998; 39: 653 52 Mather SJ & Ellison D. Reduction mediated technetium-99m labelling of monoclonal antibodies. J Nucl Med 1990; 31: 692 7 53 Stalteri MA, Mather SJ, Belinka BA, Coughlin DJ, Chengazi VU, Britton KE. Site specific conjugation and labelling of prostate antibody 7E11C5.3 (CYT-351) with technetium-99m. Eur J Nucl Med 1997; 24: 651 4 54 Feneley MR, Chengazi VU, Kirby RS et al. Prostatic radioimmunoscintigraphy: preliminary results using technetium-labelled monoclonal antibody CYT-351. Br J Urol 1996; 77: 373 81 55 Chengazi VU, Feneley MR, Ellison D et al. Imaging prostate cancer with Technetium-99m-7E11-C5.3. J Nucl Med 1997; 38: 675 82 56 Berry MG, Feneley MR, Domizio P, Britton KE, Badenoch DF. Evaluating the return of prostate adenocarcinoma. J Roy Soc Med 1998; 91: 641 3 57 Naseem MS, January HA, Britton KE, Nargund VH. Splenic metastases from adenocarcinoma of the prostate. Br J Urol 1998; 82: 597 8 58 Biassoni L, Granowska M, Carroll MJ et al. Tc-99m labelled SM3 in the preoperative evaluation of axillary lymph nodes and primary breast cancer with change detection statistical processing as an aid to tumour detection. Br J Cancer 1998; 77: 131 8 59 Jan H, Nasreen F, Van Trappen P et al. Tc-99m SM3 immunoscintigraphy to determine whether or not pelvic ultrasound abnormalities are malignant. Nucl Med Commun 1999; 20: 473 60 Manyak MJ. Clinical applications of radio-immunoscintigraphy with prostate specific antibodies for prostate cancer. Cancer Control 1998; 5: 493 9 61 Polascik TJ, Manyak MJ, Haseman MK et al. Comparison of clinical staging algorithms and 111-indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. Cancer 1999; 85: 1586 92 62 Kahn D, Williams RD, Haseman MK et al. Radio-immunoscintigraphy with In-111 labelled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. J Clin Oncol 1998; 16: 284 9 Citing Literature Volume86, Issues1July 2000Pages 135-142 ReferencesRelatedInformation
Referência(s)